All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

The extracellular matrix (ECM) is the backbone of all tissues. It is composed of several structural proteins, including collagens, which play a vital role for the function and maintenance of normal tissue function. Collagen type I and III are the most abundant collagens of the interstitial matrix and essential for its structure. The basement membrane, underlying epithelial or endothelial cells, primarily consist of collagen type IV which ensure optimal cell polarization and function \[[@pone.0194458.ref001],[@pone.0194458.ref002]\].

ECM tissue turnover, i.e. the tight balance between protein degradation and formation can be classified as two processes: 1) tissue modeling, occurring during development and growth where new tissue is being generated; 2) tissue remodeling, where functional tissue is being maintained by replacing old and damaged proteins with new ones \[[@pone.0194458.ref003],[@pone.0194458.ref004]\]. Every healthy organ is undergoing continuous remodeling with a tight control between degradation and formation. However, this delicate balance might be disturbed, leading to connective tissue disorders such as fibrosis and cancer \[[@pone.0194458.ref005]\]. Measurements of ECM turnover products in blood have shown that circulating components of the ECM, especially collagens, are elevated in fibrotic diseases \[[@pone.0194458.ref006]--[@pone.0194458.ref010]\] and cancer \[[@pone.0194458.ref011],[@pone.0194458.ref012]\]. We have developed a panel of serum-based assays specifically measuring collagen fragments that reflect either degradation or formation separately \[[@pone.0194458.ref013]--[@pone.0194458.ref018]\]. The principle behind these assays is the use of monoclonal antibodies exclusively reacting with a specific fragment of a certain protein which become exposed after specific protease-mediated degradation. Antibodies raised against pro-peptides of pro-collagens reflect collagen formation whereas antibodies recognizing small neo-epitopes on peptides derived from collagen degradation of the triple helical region represent collagen degradation \[[@pone.0194458.ref005],[@pone.0194458.ref019],[@pone.0194458.ref020]\]. [Table 1](#pone.0194458.t001){ref-type="table"} summarizes the assays we have used in this study and which ECM process they represent.

10.1371/journal.pone.0194458.t001

###### Description of the collagen degradation and formation assays used in this study.

![](pone.0194458.t001){#pone.0194458.t001g}

  Biomarker                          Specification                                                                Process                         Surrogate measure
  ---------------------------------- ---------------------------------------------------------------------------- ------------------------------- --------------------------
  C1M\[[@pone.0194458.ref014]\]      Neo-epitope of MMP-2,9,13 mediated degradation of type I collagen            Type I collagen degradation     Chronic inflammation
  PINP\[[@pone.0194458.ref013]\]     Internal epitope in the N-terminal pro-peptide of type I collagen            Type I collagen formation       Primarily bone synthesis
  C3M\[[@pone.0194458.ref016]\]      Neo-epitope of MMP-9 mediated degradation of type III collagen               Type III collagen degradation   Chronic inflammation
  Pro-C3\[[@pone.0194458.ref015]\]   Released N-terminal pro-peptide of type III collagen                         Type III collagen formation     Fibrosis
  C4M\[[@pone.0194458.ref018]\]      Neo-epitope of MMP-2,9,12 mediated degradation of type IV collagen alpha 1   Type IV collagen degradation    Chronic inflammation
  P4NP7S\[[@pone.0194458.ref017]\]   Internal epitope in the 7S domain of type IV collagen                        Type IV collagen formation      Fibrosis

PINP, which measures the N-terminal pro-peptide released during collagen formation, have been showed to primarily reflect synthesis of bone matrix \[[@pone.0194458.ref021]\]. C1M, which measures a MMP-degraded fragment of type I collagen released during tissue remodeling, is closely related to chronic inflammation with high levels being present in various inflammatory diseases \[[@pone.0194458.ref014],[@pone.0194458.ref022]--[@pone.0194458.ref025]\]. Pro-C3 measures the pro-peptide of type III collagen, i.e. synthesis, and C3M measures a MMP-generated type III collagen fragment, i.e. degradation. Increased levels of Pro-C3 and C3M have also been linked to inflammatory diseases and especially fibrosis \[[@pone.0194458.ref025]--[@pone.0194458.ref030]\]. P4NP7S, which reflects type IV collagen formation by measuring the 7S domain of type IV collagen, has been associated with fibrosis of the liver \[[@pone.0194458.ref031]\] and C4M, which reflects MMP-mediated degradation of the basement membrane, is elevated in patients with diseases displaying chronic inflammation \[[@pone.0194458.ref018],[@pone.0194458.ref024],[@pone.0194458.ref032]--[@pone.0194458.ref034]\].

While it has been shown that levels of ECM proteins vary significantly with age \[[@pone.0194458.ref035]--[@pone.0194458.ref039]\], a collagen turnover profile in men and women of varying age using a well-defined panel of markers directly measuring degradation and formation of interstitial matrix and basement membrane collagens has never been publihsed. In this study, we investigated age- and sex-dependent ECM turnover as function of age in healthy men and women by measuring biomarkers of formation and degradation of the most abundant collagens of the interstitial matrix (collagen type I and III) and basement membrane (collagen type IV) in serum.

Materials and methods {#sec002}
=====================

Serum samples {#sec003}
-------------

The serum samples used in this study originated from a population-based cross-sectional study where subjects were recruited in 2007--2011 from a random sample of all districts in Berlin provided by the resident registration office. A total number of 617 subjects, comprising 303 healthy men and 314 healthy women aged 22--86, were included in this study. Characteristics of the study population are presented in [Table 2](#pone.0194458.t002){ref-type="table"}.

10.1371/journal.pone.0194458.t002

###### Basal characteristics of the study population.
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  --------------------- -------------------------- -------------------------- -------------------------- ------------------------------------
  **Men (n = 303)**                                                                                      

  **Age group**         **Age (median, years)**\   **Weight (median, kg)**\   **Height (median, cm)**\   **BMI (median, kg/m**^**2**^**)**\
                        **Range (min.-max.)**      **Range (min.-max.)**      **Range (min.-max.)**      **Range (min.-max.)**

  **20--24 (n = 19)**   24\                        75\                        181\                       23.1\
                        22--24                     58--128                    170--197                   19.8-37-4

  **25--29 (n = 25)**   26\                        76\                        179\                       23.8\
                        25--29                     61--104                    168--202                   20.5--30.0

  **30--34 (n = 24)**   31\                        78\                        178\                       24.7\
                        30--34                     64--120                    164--189                   18.7--35.8

  **35--39 (n = 24)**   36\                        83\                        180\                       26.1\
                        35--37                     64--120                    167--193                   19.0--38.0

  **40--44 (n = 21)**   43\                        87\                        179\                       26.5\
                        40--44                     53--122                    164--195                   19.7--36.4

  **45--49 (n = 18)**   48\                        85\                        178\                       26.2\
                        45--49                     69--101                    169--199                   22.0--30.4

  **50--54 (n = 24)**   52\                        83\                        181\                       25.5\
                        50--54                     57--106                    171--188                   17.1--32.4

  **55--59 (n = 28)**   57\                        54\                        177\                       27.0\
                        55--59                     57--101                    159--192                   20.7--34.5

  **60--64 (n = 23)**   63\                        82\                        176\                       26.1\
                        60--64                     70--109                    166--197                   22.9--34.9

  **65--69 (n = 30)**   67\                        83\                        172\                       27.1\
                        65--69                     50--126                    161--183                   17.8--38.7

  **70--74 (n = 20)**   72\                        84\                        175\                       29.0\
                        70--74                     67--102                    158--184                   22.2--33.6

  **75--79 (n = 17)**   79\                        77\                        169\                       27.0\
                        77--79                     60--118                    159--183                   23.9--36.4

  **80+ (n = 30)**      82\                        78\                        175\                       25.8\
                        80--86                     52--99                     161--182                   16.1--30.8

  **Women (n = 314)**                                                                                    

  **Age group**         **Age (median, years)**\   **Weight (median, kg)**\   **Height (median, cm)**\   **BMI (median, kg/m**^**2**^**)**\
                        **Range (min.-max.)**      **Range (min.-max.)**      **Range (min.-max.)**      **Range (min.-max.)**

  **20--24 (n = 12)**   23\                        63\                        173\                       21.7\
                        22--24                     48--105                    158--184                   18.6--33.1

  **25--29 (n = 29)**   26\                        62\                        166\                       21.4\
                        25--29                     52--74                     157--180                   18.5--27.9

  **30--34 (n = 22)**   32\                        65\                        168\                       22.2\
                        30--34                     46--90                     154--186                   19.4--31.9

  **35--39 (n = 25)**   36\                        72\                        164\                       25.1\
                        35--37                     51--93                     155--185                   18.8--34.0

  **40--44 (n = 26)**   43\                        69\                        168\                       23.7\
                        40--44                     50--89                     157--183                   17.7--33.6

  **45--49 (n = 24)**   48\                        76\                        166\                       26.8\
                        45--49                     51--95                     146--180                   18.5--36.1

  **50--54 (n = 25)**   52\                        66\                        165\                       23.1\
                        50--54                     52--104                    156--173                   20.8--36.4

  **55--59 (n = 26)**   57\                        66\                        163\                       25.4\
                        55--59                     50--87                     155--175                   19.1--32.0

  **60--64 (n = 32)**   62\                        67\                        161\                       26.1\
                        60--64                     53--109                    154--172                   20.5--38.9

  **65--69 (n = 29)**   67\                        64\                        161\                       24.9\
                        65--69                     47--97                     152--171                   19.2--33.6

  **70--74 (n = 20)**   72\                        69\                        159\                       27.0\
                        70--74                     53--79                     146--175                   21.6--31.7

  **75--79 (n = 21)**   78\                        70\                        160\                       26.5\
                        75--79                     56--108                    147--171                   21.7--38.3

  **80+ (n = 23)**      81\                        64\                        159\                       25.3\
                        80--86                     46--79                     147--177                   20.1--31.7
  --------------------- -------------------------- -------------------------- -------------------------- ------------------------------------

Venous blood samples were collected by trained medical technologists between 08:00 and 10:00 AM after a 12 h fasting period. 30 min. after blood drawing, samples were centrifuged at 3500 rpm for 10 min, serum was obtained and samples were stored at -80°C until analysis.

The study was approved by the local ethics committee (Ethikkommission der Charité, Charité --Universitätsmedizin Berlin, EA4/095/05) as well as the German Radiation Protection Ordinance (Z5-22462/2-2005-063). Written informed consent was obtained from all participants before they were included into the study and the study was carried out in accordance with ICH-GCP and according to the Declaration of Helsinki.

Collagen turnover biomarker analysis {#sec004}
------------------------------------

All biomarker assays were manufactured by Nordic Bioscience (Herlev Denmark) and performed according to the manufacturer's specifications. The assays are competitive ELISA's which have been thoroughly validated for their use in human serum samples and technically characterized with regards to linearity, accuracy and reproducibility (the original assay reference for each biomarker is listed in [Table 1](#pone.0194458.t001){ref-type="table"}). To eliminate/reduce inter-assay variation, all biochemical markers were measured using a single lot of reagents and serum controls were included on each plate. Females and males, as well as age-groups were randomly distributed on the different ELISA plates. All samples were analyzed by a CAP/CLIA-accredited laboratory (Nordic Bioscience Laboratory, Herlev, Denmark).

The neo-epitope biomarkers of matrix metalloproteinase (MMP) degraded type I, type III and type IV collagen (C1M, C3M, C4M) and type I, type III and type IV collagen formation products (PINP, Pro-C3, P4NP7S) were assessed in serum as previously described \[[@pone.0194458.ref013]--[@pone.0194458.ref018]\]. Briefly, 96-well pre-coated streptavidin plates were coated with biotinylated synthetic peptides specific for the protein of interest and incubated for 30 minutes at 20°C. 20 μL of standard peptide or pre-diluted serum sample were added to designated wells followed by the addition of peroxidase-conjugated specific monoclonal antibodies and incubated for 1 h at 20°C or overnight at 4°C. Finally, tetramethylbenzinidine (TMB) (cat. 438OH, Kem-En-Tec Diagnostics, Denmark) was added to each well and the plates were incubated for 15 minutes at 20°C. All incubation steps included shaking at 300 rpm and after each incubation step, the plates were washed five times with wash buffer (20 mM Tris, 50 mM NaCl, pH 7.2). The enzymatic reaction was stopped by adding 0.18 M H~2~SO~4~ and absorbance was measured at 450 nm with 650 nm as reference. A calibration curve was plotted using a 4-parameter logistic curve fit.

Statistical analysis {#sec005}
--------------------

Subjects were stratified into 5-year interval age groups. To investigate if the biomarkers changed with age, the levels of the individual biomarkers in each 5-year age group were compared using a Kruskal---Wallis ANOVA ([S1 Table](#pone.0194458.s001){ref-type="supplementary-material"}). The p-values were adjusted to account for multiple comparisons using Dunnett´s method. An increase or decrease is defined as a significant difference between two following age groups, e.g. age group 25--29 vs. 30--34 (two adjacent age groups).

To investigate if the biomarkers varied according to sex, the level of the individual biomarkers between men and women in the five-year age groups was compared using the Mann-Whitney test. Serum biomarker data can be found in [S1 Data](#pone.0194458.s002){ref-type="supplementary-material"}. Graph design and statistical analyses were performed using GraphPad Prism version 7.03 (GraphPad Software, Inc., CA, USA).

Results {#sec006}
=======

Age specific changes in collagen remodeling {#sec007}
-------------------------------------------

### Type I collagen {#sec008}

Type I collagen formation and degradation were measured with the PINP and C1M assays, respectively. In men, the highest level of PINP was found at age 20--24 ([Fig 1A](#pone.0194458.g001){ref-type="fig"}).

![Type I collagen turnover as function of age.\
Biomarkers reflecting degradation and formation of type I collagen were measured in serum from 303 healthy men and 314 healthy women aged 22--86 divided into 5-year age groups. (A) Formation of interstitial type I collagen (PINP) and (B) degradation of interstitial type I collagen (C1M). Statistical significance of C1M and PINP between each age group was calculated using ANOVA comparing the mean of each group with the mean of every other group and is presented at the different age groups in [S1 Table](#pone.0194458.s001){ref-type="supplementary-material"}. All data are shown as median and interquartile range.](pone.0194458.g001){#pone.0194458.g001}

The level declined with increasing age. Comparing the level at age 20--24 with the rest of the age-groups, a significant decrease was observed from age 45--49 to 80+ ([S1 Table](#pone.0194458.s001){ref-type="supplementary-material"}). In women, the highest level of PINP was found at age 20--24 and 80+. PINP levels decreased from age 20--24 until age 35--39, but not significantly ([Fig 1A](#pone.0194458.g001){ref-type="fig"}). Around menopause (average age 40--60 \[[@pone.0194458.ref040]\]) the level significantly increased until age 60--64 ([S1 Table](#pone.0194458.s001){ref-type="supplementary-material"}).

The level of C1M in men was relatively stable with no significant changes ([Fig 1B](#pone.0194458.g001){ref-type="fig"}). The level of C1M in women was also relatively stable with only a significant increase between age group 40--44 and 70--74 ([Fig 1B](#pone.0194458.g001){ref-type="fig"}) ([S1 Table](#pone.0194458.s001){ref-type="supplementary-material"}).

### Type III collagen {#sec009}

The ELISA assays Pro-C3 and C3M were used to measure type III collagen formation and degradation, respectively. Pro-C3 levels in men showed a significant decrease between age 20--24 and 45--49 followed by a significant increase until age 80+ ([Fig 2A](#pone.0194458.g002){ref-type="fig"}) ([S1 Table](#pone.0194458.s001){ref-type="supplementary-material"}).

![Type III collagen turnover as function of age.\
Biomarkers reflecting degradation and formation of type III collagen were measured in serum from 303 healthy men and 314 healthy women aged 22--86 divided into 5-year age groups. (A) Formation of interstitial type III collagen (Pro-C3) and (B) degradation of interstitial type III collagen (C3M). Statistical significance of C3M and Pro-C3 between each age group was calculated using ANOVA comparing the mean of each group with the mean of every other group and is presented at the different age groups in [S1 Table](#pone.0194458.s001){ref-type="supplementary-material"}. All data are shown as median and interquartile range.](pone.0194458.g002){#pone.0194458.g002}

The level of Pro-C3 was relatively stable in women with no significant changes until age 45--49. A significant increase from age 45--49 and 55--59 until age 80+ was observed ([Fig 2A](#pone.0194458.g002){ref-type="fig"}) ([S1 Table](#pone.0194458.s001){ref-type="supplementary-material"}).

The level of C3M in men was relatively stable from age 20--80+ with no significant changes ([Fig 2B](#pone.0194458.g002){ref-type="fig"}). The same pattern was seen in women ([Fig 2B](#pone.0194458.g002){ref-type="fig"}). However, around menopause (average age 40--60 \[[@pone.0194458.ref040]\]) the level significantly increased until age 55--59 ([S1 Table](#pone.0194458.s001){ref-type="supplementary-material"}) followed by a steep significant decline ([S1 Table](#pone.0194458.s001){ref-type="supplementary-material"}).

### Type IV collagen {#sec010}

Type IV collagen formation and degradation were measured with the P4NP7S and C4M assays, respectively. The level of P4NP7S in men and women was relatively stable with no significant changes across the age span ([Fig 3A](#pone.0194458.g003){ref-type="fig"}).

![Type IV collagen turnover as function of age.\
Biomarkers reflecting degradation and formation of type IV collagen were measured in serum from 303 healthy men and 314 healthy women aged 22--86 divided into 5-year age groups. (A) Formation of basement membrane type IV collagen (P4NP7S) and (B) degradation of basement membrane type IV collagen (C4M). Statistical significance of C4M and P4NP7S between each age group was calculated using ANOVA comparing the mean of each group with the mean of every other group and is presented at the different age groups in [S1 Table](#pone.0194458.s001){ref-type="supplementary-material"}. All data are shown as median and interquartile range.](pone.0194458.g003){#pone.0194458.g003}

The same pattern was observed with C4M in men ([Fig 3B](#pone.0194458.g003){ref-type="fig"}). In women, a significant increase was observed from age 25--29 reaching a maximum at age 55--59 ([Fig 1F](#pone.0194458.g001){ref-type="fig"}) ([S1 Table](#pone.0194458.s001){ref-type="supplementary-material"}). The level significantly decreased reaching its starting level at age 80+ ([S1 Table](#pone.0194458.s001){ref-type="supplementary-material"}).

Sex specific changes in collagen remodeling {#sec011}
-------------------------------------------

### Type I collagen {#sec012}

For PINP, the starting level was significantly higher in men compared to women until the age of 45--49 ([Table 3](#pone.0194458.t003){ref-type="table"}).

10.1371/journal.pone.0194458.t003

###### Sex-specific changes in collagen remodeling.

![](pone.0194458.t003){#pone.0194458.t003g}

  --------------- ------------------ -------------------- ----------------- ------------- ------------------ -------------------- ----------------- -------------
                  **PINP**           **C1M**                                                                                                        
  **Age group**   **Median (men)**   **Median (women)**   **Significant**   **P-value**   **Median (men)**   **Median (women)**   **Significant**   **P-value**
  **20--24**      91.8               61.2                 Yes               0.02          23.2               28.2                 No                0.18
  **25--29**      80.1               53.2                 Yes               0.0004        23.0               25.5                 No                0.05
  **30--34**      72.9               50.7                 Yes               0.001         23.0               25.2                 No                0.84
  **35--39**      62.5               35.8                 Yes               0.0004        24.6               29.4                 No                0.11
  **40--44**      56.3               37.0                 Yes               0.001         25.8               20.9                 No                0.25
  **45--49**      50.3               38.4                 No                0.18          22.0               24.9                 No                0.38
  **50--54**      46.7               55.0                 No                0.34          22.8               26.0                 No                0.82
  **55--59**      44.4               56.2                 Yes               0.01          25.6               24.4                 No                0.85
  **60--64**      33.2               64.7                 Yes               \<0.0001      25.2               26.1                 No                0.66
  **65--69**      36.1               59.9                 Yes               0.001         26.5               26.0                 No                0.62
  **70--74**      37.3               48.9                 No                0.19          27.0               32.4                 No                0.27
  **75--79**      44.6               57.4                 No                0.10          22.5               26.3                 No                0.67
  **80+**         45.1               62.5                 Yes               0.02          26.2               24.4                 No                0.90
                  **PRO-C3**         **C3M**                                                                                                        
  **Age group**   **Median (men)**   **Median (women)**   **Significant**   **P-value**   **Median (men)**   **Median (women)**   **Significant**   **P-value**
  **20--24**      8.9                9.1                  No                0.80          9.9                11.8                 No                0.07
  **25--29**      8.3                8.6                  No                0.66          9.2                10.8                 No                0.21
  **30--34**      7.8                8.9                  No                0.85          10.1               9.7                  No                0.68
  **35--39**      8.3                8.0                  No                0.25          9.4                10.1                 No                0.30
  **40--44**      7.6                8.0                  No                0.87          8.3                9.1                  No                0.33
  **45--49**      7.0                6.8                  No                0.94          9.4                9.1                  No                0.78
  **50--54**      7.2                7.4                  No                0.70          9.6                11.2                 No                0.24
  **55--59**      8.2                6.8                  Yes               0.03          9.6                11.9                 Yes               0.02
  **60--64**      8.7                7.9                  No                0.38          9.9                9.4                  No                0.49
  **65--69**      7.3                7.2                  No                0.31          9.0                9.7                  No                0.20
  **70--74**      8.9                7.2                  Yes               0.04          9.7                10.1                 No                0.25
  **75--79**      9.5                7.6                  Yes               0.01          9.3                9.1                  No                0.64
  **80+**         8.9                9.7                  No                0.29          10.5               9.7                  No                0.34
                  **P4NP7S**         **C4M**                                                                                                        
  **Age group**   **Median (men)**   **Median (women)**   **Significant**   **P-value**   **Median (men)**   **Median (women)**   **Significant**   **P-value**
  **20--24**      199.5              245.2                No                0.20          15.9               18.4                 Yes               0.04
  **25--29**      185.3              210.9                No                0.49          15.5               16.8                 No                0.56
  **30--34**      224.9              205.6                No                0.52          17.4               17.6                 No                0.89
  **35--39**      182.3              200.8                No                0.27          16.1               19.1                 No                0.50
  **40--44**      190.6              193.3                No                0.82          17.6               18.9                 No                0.70
  **45--49**      202.5              194.2                No                0.72          18.3               17.5                 No                0.36
  **50--54**      212.3              206.8                No                0.77          19.6               20.8                 No                0.58
  **55--59**      196.7              230.3                Yes               0.02          17.4               22.6                 Yes               0.001
  **60--64**      200.3              225.2                No                0.88          19.5               19.9                 No                1.00
  **65--69**      190.7              196.9                No                0.31          19.0               19.5                 No                0.25
  **70--74**      199.5              245.2                No                0.20          15.9               18.4                 Yes               0.04
  **75--79**      185.3              210.9                No                0.49          15.5               16.8                 No                0.56
  **80+**         224.9              205.6                No                0.52          17.4               17.6                 No                0.89
  --------------- ------------------ -------------------- ----------------- ------------- ------------------ -------------------- ----------------- -------------

The level of the individual biomarkers between men and women in the five-year age groups was compared using the Mann-Whitney test. P-values are indicated and represent significant difference (p≤0.05) between men and women.

Around this age, the level starts to increase in women, whereas the level in men continues to decrease. In the postmenopausal period (age 60--80+), the level was significantly higher in women compared to men, except at the age of 70--79 ([Table 3](#pone.0194458.t003){ref-type="table"}).

For C1M, no significant difference between the sexes was observed.

### Type III collagen {#sec013}

The level of Pro-C3 was significantly different in women compared to men in specific age groups in the end of the menopausal period (age 55--59) and the postmenopausal period (70--74 and 75--79) with men having the highest level ([Table 3](#pone.0194458.t003){ref-type="table"}).

For C3M, a significantly higher level was observed in women as compared to men at the age of 55--59 (menopausal period) ([Table 3](#pone.0194458.t003){ref-type="table"}).

### Type IV collagen {#sec014}

As with C3M, a significantly higher level of P4NP7S in women at age 55--59 was observed ([Table 3](#pone.0194458.t003){ref-type="table"}). The level of C4M was significant different in men and women at age 20--24 and 55--59 with women having the highest level ([Table 3](#pone.0194458.t003){ref-type="table"}).

Discussion {#sec015}
==========

The present study defines a collagen turnover profile of the main collagens of the interstitial matrix (type I and III collagen) and basement membrane (type IV collagen) as function of age in healthy men and women. The main findings of the study were: 1) age specific changes in collagen turnover was most profound for type I collagen with its formation being strongly age-dependent and 2) sex specific changes in collagen turnover was most apparent during the menopausal and post-menopausal periods with the interstitial matrix and basement membrane being differently regulated. To our knowledge, this is the first time a collagen turnover profile measuring collagen formation and degradation separately, has been established in healthy men and women across the age span of adults.

Type I collagen is the main ECM component of bone, composing 90% of the organic matrix \[[@pone.0194458.ref041]\] and its formation seems to be strongly age-dependent ([Fig 1A](#pone.0194458.g001){ref-type="fig"}). The level of PINP was higher in young men and women compared to older subjects with a progressive decrease until the age around 50. This observation is in accordance with previous studies showing a decrease in women between age 30--35, stable level from age 35--45 followed by an increase until the age of 65 \[[@pone.0194458.ref035],[@pone.0194458.ref037]\]. In men, a significant decrease with age has also been observed \[[@pone.0194458.ref037]\]. The decline in PINP levels until middle-age may reflect a shift from bone modeling (formation) in childhood and early adulthood to bone remodeling (maintenance). As seen in [Fig 1B](#pone.0194458.g001){ref-type="fig"}, degradation of type I collagen (C1M) is relatively stable throughout the study period. As C1M is a marker of tissue inflammation and does not represent bone degradation \[[@pone.0194458.ref014]\], this may explain why C1M is not age-dependent and PINP is. One may argue that elder subjects have more inflammation than younger, hence a rise in C1M late in life was expected. However, the observed results may reflect that the elder subjects in this study are "super" healthy compared to the "normal" elder population.

Type III collagen is one of the main interstitial collagens and structurally similar to type I collagen. Despite being often associated with type I collagen, the formation of type III collagen showed a different pattern with an increase in both men and women after age 45--49 and 55--59 respectively. As Pro-C3 is a marker of fibrosis \[[@pone.0194458.ref015],[@pone.0194458.ref029],[@pone.0194458.ref042]\], these results suggest that tissue fibrosis increases with advancing age.

Type IV collagen is one of the most abundant components of the basement membrane. No association between age and biomarker level (P4NP7S and C4M) was observed, however C4M in women was significantly increased with time comparing age 25--29 with age 55--59 ([Fig 3B](#pone.0194458.g003){ref-type="fig"}, [S1 Table](#pone.0194458.s001){ref-type="supplementary-material"}). These data suggest that basement membrane degradation is increased in the menopausal period.

Karsdal *et al*.\[[@pone.0194458.ref003]\] have conducted a study similar to this in rats. They found that type I collagen had an increased turnover in younger rats compared to old rats consistent with our findings. Type III collagen turnover was not significantly influenced by age while type IV collagen degradation was slightly upregulated in younger animals. These results can be translated into the present data in humans which is of importance when conducting pre-clinical and clinical studies in ECM remodeling diseases.

To investigate sex-specific changes in collagen turnover, the level of the individual biomarkers between men and women in the five-year age groups was compared. C3M, P4NP7S and C4M showed a significant difference between men and women in the menopausal period (age 40--60) with women having a higher level of collagen remodeling. PINP and Pro-C3 displayed an increase in women compared to men in the post-menopausal period (after the age of 60). PINP showed a significant lower level in women throughout the pre-menopausal period (before the age of 40). Together, these data suggest that hormonal status might affect collagen remodeling. Whether this is related to estrogen levels or other menopausal mechanisms needs further investigations. However, the fact that the biomarkers decreases again during the post-menopausal period indicates that a specific event during menopause is somehow influencing the collagen turnover. These sex-specific changes in collagen turnover could be associated with diseases that is more prevalent in postmenopausal women, as with osteoporosis and PINP \[[@pone.0194458.ref043]\].

One limitation of this study is the lack of younger subjects. Studies measuring the aminoterminal pro-peptide of procollagen type III have shown a high level in young children which decreased with advancing age with a short increase around puberty \[[@pone.0194458.ref038],[@pone.0194458.ref039]\]. These data may reflect the process of modeling where new tissue is being formed during growth whereas the results of the current study only reflects the end of this process involving a shift towards ECM remodeling. Another limitation is the lack of information on the subject's renal function. We are currently investigating the association between renal function and the collagen turnover biomarkers. Unpublished data from our group show no association between renal function and C1M, PINP, C3M, PRO-C3 and C4M.

Subjects with ECM remodeling disorders, such as fibrosis and cancer, have been shown to have a different ECM turnover compared to healthy individuals \[[@pone.0194458.ref018],[@pone.0194458.ref022],[@pone.0194458.ref025],[@pone.0194458.ref029],[@pone.0194458.ref033],[@pone.0194458.ref044]\] and attention has been drawn towards the involvement of matrix proteins in ECM remodeling disorders \[[@pone.0194458.ref045],[@pone.0194458.ref046]\]. For example in cancer, it is now becoming evident that the tumor milieu, i.e. the ECM, is just as important as the tumor itself for tumor progression and metastasis \[[@pone.0194458.ref047],[@pone.0194458.ref048]\]. The ability to measure changes in ECM turnover in ECM-involved pathologies, could be an important step towards a better personalized medicine \[[@pone.0194458.ref049],[@pone.0194458.ref050]\].

The presented data are important to consider when conducting clinical studies focusing on ECM-related disorders as these biomarkers have been shown to associate with various connective tissue disorders where the ECM balance is skewed \[[@pone.0194458.ref005],[@pone.0194458.ref015],[@pone.0194458.ref018],[@pone.0194458.ref022],[@pone.0194458.ref025],[@pone.0194458.ref029],[@pone.0194458.ref033],[@pone.0194458.ref044]\].

Conclusions {#sec016}
===========

In conclusion, collagen turnover is affected by age and sex with the interstitial matrix (type I and III collagen) and the basement membrane (type IV collagen) being differently regulated. We have established an age- and sex-dependent collagen turnover profile in healthy men and women and the observed changes needs to be accounted for when measuring ECM related biomarkers.
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###### Age-related changes in collagen remodeling.

Statistical significance (p-value) for each biomarker calculated using ANOVA comparing the mean of each group with the mean of every other group. Ns refers to no significance. The following biomarkers showed no significance and are therefore not presented: C1M (men), C3M (men), P4NP7S (men and women) and C4M (men).

(DOCX)
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Click here for additional data file.

###### Serum biomarker data for each subject.

(XLSX)
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Click here for additional data file.
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